Biogen will buy Reata Pharmaceuticals and its Friedreich’s ataxia drug in a $7.3 billion deal.
Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
Biogen will buy Reata Pharmaceuticals and its Friedreich’s ataxia drug in a $7.3 billion deal.